MetaCap

Alto Neuroscience (ANRO) vs Omeros (OMER)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Alto Neuroscience (ANRO) has outperformed Omeros (OMER) over the past year, gaining 91.5% versus a gain of 48.9%. Alto Neuroscience is the larger company by market cap ($1.02 billion vs $983.7 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ANRO+91.47%OMER+48.93%
+186%+87%-12%
Nov 21, 20251 yearNov 20, 2026
ANRO+22.56%OMER+288.53%
+520%+200%-120%
Jan 29, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ANRO versus OMER key metrics
MetricANROOMER
Share price$25.37$13.21
Market cap$1.02B$983.66M
1-day change-4.30%-5.71%
YTD return+42.53%-23.11%
1-year return+91.47%+48.93%
5-year return—+77.79%
P/E ratio (TTM)—15.92
Forward P/E—11.95
EPS (TTM)$-2.32$0.83
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-63.24M$-3.35M
52-week high$37.48$21.24
52-week low$12.51$6.70
Distance from 52-week high-32.31%-37.81%
Analyst consensusstrong_buybuy
Avg. price target upside+52.42%+108.18%
Average volume614.92K1.36M
Shares outstanding40.11M74.46M
Employees68175
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ANRO has outperformed OMER by 42.5 percentage points over the past year.

About Alto Neuroscience

ANRO stock →

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 68 employees

About Omeros

OMER stock →

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome.

Health Care · Biotechnology: Pharmaceutical Preparations · 175 employees

ANRO vs OMER FAQ

Which is bigger, Alto Neuroscience or Omeros?

Alto Neuroscience (ANRO) is larger, with a market capitalization of $1.02B compared with $983.66M for Omeros (OMER).

Which stock has performed better over the past year, ANRO or OMER?

ANRO returned +91.47% over the past 12 months, compared with +48.93% for OMER (price return, excluding dividends). Past performance does not predict future results.

Are Alto Neuroscience and Omeros in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons